The induced pluripotent stem cell (ipsc) market size has grown rapidly in recent years. It will grow from $2.97 billion in 2023 to $3.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historical period can be attributed to the increasing healthcare expenditure, a surge in funding, growing awareness of the medicinal potential of stem cell products, the utilization of induced pluripotent stem cell (iPSC) based drug discovery, a rising demand for personalized medicine, and the cost-effective benefits of iPSC for drug discovery.
The induced pluripotent stem cell (ipsc) market size is expected to see rapid growth in the next few years. It will grow to $4.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of chronic diseases, the expansion of genomic projects, advancements in the development of iPSC-derived disease models, a rise in the prevalence of genetic diseases, government initiatives, and a rapid increase in technology. Major trends expected in the forecast period encompass the development of pluripotent stem cells for Parkinson's disease (PD), strategic collaborations and partnerships, the creation of iPSC-derived NK cells, the development of induced pluripotent stem cells (iPSC) for cell therapy, significant investment in regenerative medicine research and development, the formulation of iPSC expansion mediums, the creation of personalized iPSC, and the development of pluripotent stem cells for Type I diabetes.
The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.
Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.
Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.
Major players in the induced pluripotent stem cell market are intensifying their focus on introducing personalized induced pluripotent stem cells, exemplified by offerings such as Personal iPS. REPROCELL, a stem cell research company, launched Personal iPS in January 2021, providing a flexible and customizable service for reprogramming cells from various sources. The services include donor tissue collection, sample quarantine, derivation of primary cell lines, RNA-based iPSCs, and reprogramming technology.
In August 2021, catalant, a pharmaceutical company, acquired RheinCell Therapeutics GmbH, a move aimed at bolstering Catalent's presence in the cell and gene therapy sector and advancing therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH, based in Germany, specializes in developing human induced pluripotent stem cells (iPSCs) for next-generation cell therapies.
Major companies operating in the induced pluripotent stem cell (ipsc) market report are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc., Takara Bio, Inc., Lonza Group AG, Astellas Pharma Inc., ViaCyte, Inc., Ncardia, REPROCELL USA, Inc., Japan Tissue Engineering Co., Ltd., Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Banco de Cordon del Peru, CryoHoldco, CellSave Arabia, Life Cell, AmiCare, Cells4life, ReeLabs, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart.
North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2023. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the induced pluripotent stem cell (ipsc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.
The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The induced pluripotent stem cell (ipsc) market size is expected to see rapid growth in the next few years. It will grow to $4.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of chronic diseases, the expansion of genomic projects, advancements in the development of iPSC-derived disease models, a rise in the prevalence of genetic diseases, government initiatives, and a rapid increase in technology. Major trends expected in the forecast period encompass the development of pluripotent stem cells for Parkinson's disease (PD), strategic collaborations and partnerships, the creation of iPSC-derived NK cells, the development of induced pluripotent stem cells (iPSC) for cell therapy, significant investment in regenerative medicine research and development, the formulation of iPSC expansion mediums, the creation of personalized iPSC, and the development of pluripotent stem cells for Type I diabetes.
The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.
Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.
Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.
Major players in the induced pluripotent stem cell market are intensifying their focus on introducing personalized induced pluripotent stem cells, exemplified by offerings such as Personal iPS. REPROCELL, a stem cell research company, launched Personal iPS in January 2021, providing a flexible and customizable service for reprogramming cells from various sources. The services include donor tissue collection, sample quarantine, derivation of primary cell lines, RNA-based iPSCs, and reprogramming technology.
In August 2021, catalant, a pharmaceutical company, acquired RheinCell Therapeutics GmbH, a move aimed at bolstering Catalent's presence in the cell and gene therapy sector and advancing therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH, based in Germany, specializes in developing human induced pluripotent stem cells (iPSCs) for next-generation cell therapies.
Major companies operating in the induced pluripotent stem cell (ipsc) market report are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc., Takara Bio, Inc., Lonza Group AG, Astellas Pharma Inc., ViaCyte, Inc., Ncardia, REPROCELL USA, Inc., Japan Tissue Engineering Co., Ltd., Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Banco de Cordon del Peru, CryoHoldco, CellSave Arabia, Life Cell, AmiCare, Cells4life, ReeLabs, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart.
North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2023. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the induced pluripotent stem cell (ipsc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.
The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics3. Induced Pluripotent Stem Cell (iPSC) Market Trends and Strategies32. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Benchmarking33. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Dashboard34. Key Mergers and Acquisitions in the Induced Pluripotent Stem Cell (iPSC) Market
4. Induced Pluripotent Stem Cell (iPSC) Market - Macro Economic Scenario
5. Global Induced Pluripotent Stem Cell (iPSC) Market Size and Growth
6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation
7. Induced Pluripotent Stem Cell (iPSC) Market Regional and Country Analysis
8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market
9. China Induced Pluripotent Stem Cell (iPSC) Market
10. India Induced Pluripotent Stem Cell (iPSC) Market
11. Japan Induced Pluripotent Stem Cell (iPSC) Market
12. Australia Induced Pluripotent Stem Cell (iPSC) Market
13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market
14. South Korea Induced Pluripotent Stem Cell (iPSC) Market
15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market
16. UK Induced Pluripotent Stem Cell (iPSC) Market
17. Germany Induced Pluripotent Stem Cell (iPSC) Market
18. France Induced Pluripotent Stem Cell (iPSC) Market
19. Italy Induced Pluripotent Stem Cell (iPSC) Market
20. Spain Induced Pluripotent Stem Cell (iPSC) Market
21. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market
22. Russia Induced Pluripotent Stem Cell (iPSC) Market
23. North America Induced Pluripotent Stem Cell (iPSC) Market
24. USA Induced Pluripotent Stem Cell (iPSC) Market
25. Canada Induced Pluripotent Stem Cell (iPSC) Market
26. South America Induced Pluripotent Stem Cell (iPSC) Market
27. Brazil Induced Pluripotent Stem Cell (iPSC) Market
28. Middle East Induced Pluripotent Stem Cell (iPSC) Market
29. Africa Induced Pluripotent Stem Cell (iPSC) Market
30. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape and Company Profiles
31. Induced Pluripotent Stem Cell (iPSC) Market Other Major and Innovative Companies
35. Induced Pluripotent Stem Cell (iPSC) Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on induced pluripotent stem cell (ipsc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for induced pluripotent stem cell (ipsc)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cell Types
2) By Application: Academic Research; Drug Discovery and Toxicity Studies; Regenerative Medicine; Cell and Gene Therapy
3) By End-user: Hospitals; Research Laboratories
Key Companies Mentioned: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group AG; Astellas Pharma Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)
- Thermo Fisher Scientific, Inc
- Takara Bio, Inc
- Lonza Group AG
- Astellas Pharma Inc
- ViaCyte, Inc
- Ncardia
- REPROCELL USA, Inc
- Japan Tissue Engineering Co., Ltd
- Merck KGaA
- Cynata Therapeutics Limited
- Dainippon Sumitomo Pharma
- Shenzhen Bioscience
- Shanghai Cell Therapy Group
- Car-T Bio
- JW therapeutics
- Fosun Kite Biotechnology
- Shanghai UniCar Therapy
- Takaria Bio
- SEED Biosciences SA
- Cellerix
- CellGenix
- NsGene
- TiGenix
- Renuron Group
- Smart Cells
- Genenta Science
- Biocad Rf
- MSD
- Pfizer
- Roche
- Pharmasyntez
- Selvita
- Mabion
- Pure Biologics
- OncoArendi Therapeutics
- Proteon Pharmaceuticals
- GlaxoSmithKline
- Parexel
- Bayer
- Fate Therapeutics
- Athersys
- BrainStorm Cell Therapeutics
- Cellular Biomedicine Group
- Pluristem Therapeutics
- Gamida Cell
- VistaGen Therapeutics
- Caladrius Biosciences
- BioCanRx
- CellCAN
- CCRM
- C3i
- BioCells Argentina
- Banco de Cordon del Peru
- CryoHoldco
- CellSave Arabia
- Life Cell
- AmiCare
- Cells4life
- ReeLabs
- Stem Cells
- Royan Stem Cell Technology Co.
- Next BioSciences
- CryoSave
- BioHeart
Methodology
LOADING...